BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BIOLASE Technology, Inc. (BIOL) Awarded New Patent That Expands Intellectual Property Position in Laser Endodontics


8/1/2012 8:59:03 AM

IRVINE, CA--(Marketwire - August 01, 2012) - BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser manufacturer and distributor, today announced that the U.S. Patent and Trademark Office has awarded BIOLASE a new patent, number 8,221,117 B2, titled, "Probes and Biofluids for Treating and Removing Deposits from Tissue Surfaces."

The new patent expands the Company's intellectual property ("IP") portfolio in the area of laser endodontics to a total of 14 issued and 19 pending patents, with 8 issued and 8 pending in the U.S. and 6 issued and 11 pending in international markets. BIOLASE currently has a total of 159 issued and 130 pending patents.

Chairman and CEO Federico Pignatelli said, "Our laser endodontic therapy system has the ability to reduce root canal bacteria levels by 99.7 percent and treatment time by 10 to 15 minutes. These are significant advantages to dentists who, according to industry sources, perform an estimated 30 to 50 million root canals annually in the U.S. and who we estimate perform more than a hundred million globally. Despite various improvements in conventional root canal therapy, failure rates continue to range between 10 and 15 percent. The primary causes of this high rate of failures include under-filled or missed root canals, tooth fractures, and inadequate cleaning which result in leakage, bacterial contamination or re-contamination. These failures result in three to seven million additional advanced dental procedures annually ranging from antibiotic therapy to extraction of the infected tooth. Multiple independent studies have shown that improving the effectiveness of cleaning and disinfection at the apex of a root canal double the chance for a successful clinical outcome. We estimate that in the U.S. alone, the improved clinical outcomes facilitated by Waterlase root canal therapy could save as much as $3.5 billion annually in retreatment expenses for practitioners, insurance providers and patients."

The new patent relates to the ability of a radially firing or side firing endodontic probe to combine multiple wavelengths of infrared and near-infrared lasers, such as the Waterlase iPlus™ and iLase™ diode laser, with biofluids or biopowders comprising one or more biologically-active particles or cleaning agents. These could be cleaning or disinfectant particles, anesthetizing agents, and particles or agents suspended in a liquid. Claims also include minimally invasive access to a surgical site of tissue comprising one or more of a canal, pocket or periodontal pocket.

"We believe the elements included in this new patent, in combination with our other related IP, move us closer to our goal of having technologies and patents that offer a thorough and protected process of root canal sterilization which should attract more general practitioners and endodontists that have not yet adopted laser endodontic therapy. We remain committed to innovation that furthers our core technologies and protects our market leading position in laser dentistry," Pignatelli concluded. "This new patent reflects the strength of the overall BIOLASE patent portfolio and rewards our commitment to maintain our research and development activities at high levels to keep our technological leadership in both hard tissue and diode lasers and to advance high-tech dentistry as a real and sustainable innovation."

About BIOLASE, Inc.
BIOLASE, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 285 patented and patent pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 19,600 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.


For further information, please contact:
Jill Bertotti
Allen & Caron
+1-949-474-4300
jill@allencaron.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->